Schizophrenia Research
Volume 120, Issue 1 , Pages 23-37 , July 2010

Probably at-risk, but certainly ill — Advocating the introduction of a psychosis spectrum disorder in DSM-V

  • Stephan Ruhrmann

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Psychotherapy, University of Cologne, Kerpener Strasse 62, 50924 Cologne, Germany. Tel.: +49 221 478 4005 (secretary) -4024 (direct); fax: +49 221 478 87139.
    • Joined first authorship.
    • ,
  • Frauke Schultze-Lutter

      Affiliations

    • University Hospital of Child and Adolescent Psychiatry, University of Bern, Bern, Switzerland
    • Joined first authorship.
    • ,
  • Joachim Klosterkötter

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany

Received 9 October 2009 ,Accepted 12 March 2010.

References 

  1. Addington J, Zipursky R, Perkins D, Woods SW, Miller TJ, McGlashan TH. Decline in social functioning for those with an “at risk mental state”. Schizophr. Res. 2004;70(1):37-37
  2. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, et al. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 2007;33(3):665–672
  3. Amminger G, Schaefer MR, Papageorgiou K, Becker J, Mossaheb N, Harrigan SM, et al. Omega-3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: a doubleblind randomized, placebocontrolled treatment study. Schizophr. Bull. 2007;33(2):418–419
  4. APA . Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000;
  5. Barch DM, Keefe RS. Anticipating DSM-V: opportunities and challenges for cognition and psychosis. Schizophr. Bull. 2010;36(1):43–47
  6. Bell RQ. Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry. 1992;55(4):370–381
  7. Besthehorn M, Tischer B, Glaser P, Mast O, Schmidt D. Repräsentative Studie zur Verteilung schizophrener Patienten auf medizinische Versorgungseinrichtungen in Deutschland. Fortschr. Neurol. Psychiatr. 1999;67(11):487–492
  8. BMG, 2007. gesundheitsziele.de - Maßnahmen des Bundesministeriums für Gesundheit zur Umsetzung nationaler Gesndheitsziele. Bundesministerium für Gesundheit, Berlin.
  9. Bora E, Yücel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr. Bull. 2010;36(1):36–42
  10. Borgwardt SJ, McGuire PK, Aston J, Berger G, Dazzan P, Gschwandtner U, et al. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br. J. Psychiatry Suppl. 2007;51:s69–75
  11. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, Tendolkar I, Bechdolf A, Pukrop R, et al. Sensory Gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol. Psychiatry. 2008;64(5):376–384
  12. Broome MR, Woolley JB, Tabraham P, Johns LC, Bramon E, Murray GK, et al. What causes the onset of psychosis?. Schizophr. Res. 2005;79(1):23–34
  13. Cameron DE. Early schizophrenia. Am. J. Psychiatry. 1938;95(3):567–582
  14. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry. 2008;65(1):28–37
  15. Carr V, Halpin S, Lau N, O'Brien S, Beckmann J, Lewin T. A risk factor screening and assessment protocol for schizophrenia and related psychosis. Aust. N. Z. J. Psychiatry. 2000;34(Suppl.):S170–S180
  16. CDHAC . Promotion, Prevention and Early Intervention for Mental Health—a Monograph. Canberra: Commonwealth Department of Health and Aged Care; 2000;
  17. Clouth J. Costs of early retirement — the case of schizophrenia. Psychiatr. Prax. 2004;31(Suppl. 2):S238–S245
  18. Corcoran C, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being “at risk”. Schizophr. Res. 2005;73(2–3):173–184
  19. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr. Bull. 2003;29(4):633–651
  20. Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr. Bull. 2007;33(3):688–702
  21. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 2003;10(4):S1–S10
  22. Demjaha A, Morgan K, Morgan C, Landau S, Dean K, Reichenberg A, et al. Combining dimensional and categorical representation of psychosis: the way forward for DSM-V and ICD-11?. Psychol. Med. 2009;1–13
  23. EC . Green Paper — Improving Mental Health of the Population: Towards a Strategy on Mental Health for the European Union. Brüssel: European Communities; 2005;
  24. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am. J. Psychiatry. 1992;149(9):1148–1156
  25. Gordon RS. An operational classification of disease prevention. Public Health Rep. 1983;98(2):107–109
  26. Gourzis P, Katrivanou A, Beratis S. Symptomatology of the initial prodromal phase in schizophrenia. Schizophr. Bull. 2002;28(3):415–429
  27. Gutiérrez-Maldonado J, Caqueo-Urízar A, Kavanagh D. Burden of care and general health in families of patients with schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 2005;40(11):899–904
  28. Guyatt G, Drummond R, Meade OM, Cook DJ. Users' Guides to the Medical Literature: a Manual for Evidence-based Clinical Practice. New York: McGraw-Hill Medical; 2008;
  29. Häfner H, an der Heiden W. Course and outcome. In:  Mueser KT,  Jeste DV editor. Clinical Handbook of Schizophrenia. New York, N.Y: The Guilford Press; 2008;
  30. Häfner H, Maurer K, Löffler W, Riecher-Rössler A. The influence of age and sex on the onset and early course of schizophrenia. Br. J. Psychiatry. 1993;162(1):80–86
  31. Häfner H, Maurer K, Löffler W, an der Heiden W, Munk-Jorgensen P, Hambrecht M, et al. The ABC Schizophrenia Study: a preliminary overview of the results. Soc. Psychiatry Psychiatr. Epidemiol. 1998;33(8):380–386
  32. Häfner H, Maurer K, Löffler W, an der Heiden W, Schultze-Lutter F, Hambrecht M. Modeling the early course of schizophrenia. Schizophr. Bull. 2003;29(2):325–340
  33. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 2006;32(1):166–178
  34. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br. J. Psychiatry. 2001;178(6):506–517
  35. Hennekens CH, Buring JE. Epidemiology in Medicine. Brown and Company, Boston, Toronto: Little; 1987;
  36. Huber G. Reine Defektsyndrome und Basisstadien endogener Psychosen. Fortschr. Neurol. Psychiatr. 1966;34:409–426
  37. Huber G, Gross G, Schüttler R. Schizophrenie. Verlaufs- und sozialpsychiatrische Langzeituntersuchungen an den 1945–1959 in Bonn hospitalisierten schizophrenen Kranken. Berlin, Heidelberg: Springer; 1979;
  38. Iyer SN, Boekestyn L, Cassidy CM, King S, Joober R, Malla AK. Signs and symptoms in the pre-psychotic phase: description and implications for diagnostic trajectories. Psychol. Med. 2008;38(8):1147–1156
  39. Kahn E. Schizoid und Schizophrenie im Erbgang. In:  Rüdin E editors. Studien über die Vererbung und Entstehung geistiger Störungen, Band IV. München: Springer; 1923;
  40. Keefe RS, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007;33(4):912–920
  41. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch. Gen. Psychiatry. 2006;63(3):250–258
  42. Klosterkötter J. & Schultze-Lutter F. (in press). Prevention and early treatment, in: Helmchen. H., Sartorius, N. (Eds.), Ethics in Psychiatry - European contributions. Springer, Heidelberg.
  43. Klosterkötter J, Ebel H, Schultze-Lutter F, Steinmeyer EM. Diagnostic validity of basic symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 1996;246(3):147–154
  44. Klosterkötter J, Gross G, Huber G, Wieneke A, Steinmeyer EM, Schultze-Lutter F. Evaluation of the ‘Bonn Scale for the Assessment of Basic Symptoms BSABS’ as an instrument for the assessment of schizophrenia proneness: a review of recent findings. Neurol. Psychiat. Brain Res. 1997;5(3):137–150
  45. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry. 2001;58(2):158–164
  46. Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Salokangas RK, Linszen D, Birchwood M, et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry. 2005;4(3):161–167
  47. Köhn D, Pukrop R, Niedersteberg A, Schultze-Lutter F, Ruhrmann S, Bechdolf A, et al. Pathways to care: help-seeking behavior in first-episode psychosis. Fortschr. Neurol. Psychiatr. 2004;72(11):635–642
  48. Krueger RF, Bezdjian S. Enhancing research and treatment of mental disorders with dimensional concepts: toward DSM-V and ICD-11. World Psychiatry. 2009;8(1):3–6
  49. Lehman AF, Alexopoulos GS, Goldman H, Jeste D, B., Ü. . Mental disorders and disability: time to reevaluate the relationship?. In:  Kupfer DJ,  First MB,  Regier DA editor. A Research Agenda for DSM-V. Washington, D.C: American Psychiatric Association; 2002;
  50. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt BA. The assessment of “prodromal schizophrenia”: unresolved issues and future directions. Schizophr. Bull. 2003;29(4):717–728
  51. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 2004;68(1):37–48
  52. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophr. Res. 2004;71(2–3):227–237
  53. Mayer-Gross W. Die Klinik. In:  Bumke O editors. Handbuch der Geisteskrankheiten — Spezieller Teil V: Die Schizophrenie. Berlin: Julius Springer; 1932;
  54. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr. Bull. 1996;22(2):201–222
  55. McGlashan TH, Miller TJ, Woods SW, Rosen JL, Hoffman RE, Davidson L. Structured Interview for Prodromal Syndromes (Version 3.0). New Haven: PRIME Research Clinic, Yale School of Medicine; 2001;
  56. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry. 2006;163(5):790–799
  57. McGorry PD, Yung AR, Phillips LJ. The “close-in” or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr. Bull. 2003;29(4):771–790
  58. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust. N. Z J. Psychiatry. 2006;40(8):616–622
  59. McGorry PD, Yung AR, Bechdolf A, Amminger P. Back to the future: predicting and reshaping the course of psychotic disorder. Arch. Gen. Psychiatry. 2008;65(1):25–27
  60. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J. Clin. Psychiatry. 2009;70(9):1206–1212
  61. Meng H, Schimmelmann BG, Koch E, Bailey B, Parzer P, Günter M, et al. Basic symptoms in the general population and in psychotic and non-psychotic psychiatric adolescents. Schizophr. Res. 2009;111(1–3):32–38
  62. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry. 2002;159(5):863–865
  63. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003;29(4):703–715
  64. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry. 2004;185(4):291–297
  65. In:  Mrazek PJ,  Haggerty HJ editor. Reducing Risks for Mental Disorders: Frontiers for Preventive Research. Washington DC: Academy Press; 1994;
  66. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr. Res. 2006;83(1):29–40
  67. Norman RM, Scholten DJ, Malla AK, Ballageer T. Early signs in schizophrenia spectrum disorders. J. Nerv. Ment. Dis. 2005;193(1):17–23
  68. Pantelis C, Velakoulis D, Wood SJ, Yucel M, Yung AR, Phillips LJ, et al. Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies. Int. Rev. Psychiatry. 2007;19(4):371–381
  69. Peralta V, Cuesta MJ. The deficit syndrome of the psychotic illness. A clinical and nosological study. Eur. Arch. Psychiatry Clin. Neurosci. 2004;254(3):165–171
  70. Perivoliotis D, Morrison AP, Grant PM, French P, Beck AT. Negative performance beliefs and negative symptoms in individuals at ultra-high risk of psychosis: a preliminary study. Psychopathology. 2009;42(6):375–379
  71. Pukrop R, Schultze-Lutter F, Ruhrmann S, Brockhaus-Dumke A, Tendolkar I, Bechdolf A, et al. Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episode schizophrenia. J. Clin. Exp. Neuropsych. 2006;28(8):1388–1407
  72. Regier DA. Dimensional approaches to psychiatric classification: refining the research agenda for DSM-V: an introduction. Int. J. Methods Psychiatr. Res. 2007;16(Suppl. 1):S1–S5
  73. Riecher-Rössler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P, et al. The Basel early-detection-of-psychosis (FEPSY)-study — design and preliminary results. Acta Psychiat. Scand. 2007;115(2):114–125
  74. Rössler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol. 2005;15(4):399–409
  75. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;36(Suppl 3):S162–S167
  76. Ruhrmann S, Schultze-Lutter F, Wieneke A, Picker H, Pukrop R, Hoppmann B, et al. Do patients with a prodromal syndrome cross the threshold of clinical illness?. Schizophr. Res. 2004;70(Suppl. 1):26-26
  77. Ruhrmann S, Tepest R, Vogeley K. Frontal hypergyria in the at risk state for psychosis. Schizophr. Res. 2004;70(Suppl. 1):41–42
  78. Ruhrmann S, Bechdolf A, Kuhn KU, Wagner M, Schultze-Lutter F, Janssen B, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Brit. J. Psychiat. 2007;191:S88–S95
  79. Ruhrmann S, Paruch J, Bechdolf A, Pukrop R, Wagner M, Berning J, et al. Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiat. Scand. 2008;117(5):357–368
  80. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Intervention in the at-risk state to prevent transition to psychosis. Curr. Opin. Psychiatry. 2009;22(2):177–183
  81. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans PM, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prosepective European Prediction of Psychosis Study (EPOS). Arch. Gen. Psychiatry. 2010;67(3):241–251
  82. Sackett DL, Strauss SE, Richardson WS, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. Edinburgh: Churchill Livingstone; 2000;
  83. Samnaliev M, Clark RE. The economics of schizophrenia. In:  Mueser KT,  Jeste DV editor. Clinical Handbook of Schizophrenia. New York, N.Y: The Guilford Press; 2008;
  84. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907
  85. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr. Bull. 2009;35(1):5–8
  86. Schultze-Lutter F, Ruhrmann S, Klosterkötter J. Can schizophrenia be predicted phenomenologically?. In:  Johannesen JO,  Martindale BV,  Cullberg J editor. Evolving Psychosis: Different Stages, Different Treatments. Hove: Routledge; 2006;
  87. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer E, Ruhrmann S. Predicting first-episode psychosis by basic symptom criteria. Clin. Neuropsychiatry. 2007;4(1):11–22
  88. Schultze-Lutter F, Ruhrmann S, Hoyer C, Klosterkötter J, Leweke FM. The initial prodrome of schizophrenia: different duration, different underlying deficits?. Compr. Psychiatry. 2007;48(5):479–488
  89. Schultze-Lutter F, Ruhrmann S, Picker H, von Reventlow HG, Daumann B, Brockhaus-Dumke A, et al. Relationship between subjective and objective cognitive function in the early and late prodrome. Br. J. Psychiatry Suppl. 2007;51:s43–s51
  90. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument — Adult version (SPI-A). Rome: Giovanni Fioriti; 2007;
  91. Schultze-Lutter F, Ruhrmann S, Klosterkötter J. Early detection of psychosis — establishing a service for persons at risk. Eur. Psychiatry. 2009;24(1):1–10
  92. Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkötter J. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr. Bull. 2010;36(1):182–191
  93. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. Schizophr. Res. 2010;116(2–3):168–172
  94. Simon AE, Dvorsky DN, Boesch J, Roth B, Isler E, Schueler P, et al. Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr. Res. 2006;81(1):83–90
  95. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiat. Scand. 2007;115(1):4–11
  96. Sullivan HS. The onset of schizophrenia. Am. J. Psychiatry. 1927;84(1):105–134
  97. Svirskis T, Korkeila J, Heinimaa M, Huttunen J, Ilonen T, Ristkari T, et al. Axis-I disorders and vulnerability to psychosis. Schizophr. Res. 2005;75(2–3):439–446
  98. Tan HY, Ang YG. First-episode psychosis in the military: a comparative study of prodromal symptoms. Aust. N. Z J. Psychiatry. 2001;35(4):512–519
  99. van Os J. ‘Salience syndrome’ replaces ‘schizophrenia’ in DSM-V and ICD-11: psychiatry's evidence-based entry into the 21st century?. Acta Psychiatr. Scand. 2009;120(5):363–372
  100. van Os J. A salience dysregulation syndrome. Br. J. Psychiatry. 2009;194(2):101–103
  101. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–645
  102. van Os J, Rutten BP, Poulton R. Gene–environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr. Bull. 2008;34(6):1066–1082
  103. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol. Med. 2009;39(2):179-95
  104. WHO . International Statistical Classification of Diseases and Related Health Problems. Tenth Revision (ICD-10). Geneva: World Health Organization; 1992;
  105. WHO . Prevention of Mental Disorders: Effective Interventions and Policy Options. Geneva: World Health Organization; 2004;
  106. Witthaus H, Kaufmann C, Bohner G, Özgürdal S, Gudlowski Y, Gallinat J, et al. Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Res. 2008;173(3):163–169
  107. Woods SW. The “prodromal” patient: both symptomatic and at-risk. CNS Spectr. 2001;6(3):223–232
  108. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr. Bull. 2009;35(5):894–908
  109. Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust. N. Z J. Psychiatry. 1996;30(5):587–599
  110. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 1996;22(2):283–303
  111. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr. Res. 2003;60(1):21–32
  112. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004;67(2–3):131–142
  113. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, et al. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr. Res. 2006;84(1):57–66
  114. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry. 2005;39(11–12):964–971
  115. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, et al. Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2year follow-up. Schizophr. Res. 2008;105(1–3):10–17

PII: S0920-9964(10)01185-0

doi: 10.1016/j.schres.2010.03.015

Schizophrenia Research
Volume 120, Issue 1 , Pages 23-37 , July 2010

Article Tools